Empagliflozin and Dapagliflozin in Improving Ejection Fraction: A Prospective Observational Comparison of Clinical Outcomes and Patient Reported Quality of Life
Abstract
Abstract Background SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart function, lab tests, echocardiography, and quality of life using routine clinical data and the Kansas City Cardiomyopathy Questionnaire-12. Methods We conducted a prospective observational study with 70 heart failure patients, evenly divided between those taking empagliflozin 10 mg daily and those on dapagliflozin 10 mg daily as part of their usual care. We collected vital signs, blood tests, echocardiographic measures, including left ventricular ejection fraction, and KCCQ-12 scores. Statistical analysis included t-tests, Mann-Whitney U, Chi-square, ANOVA, Shapiro-Wilk for normality, Levene’s test for equal variances, and Pearson correlation. Results with p-values under 0.005 were considered significant. Results The groups were similar in age, gender, rates of hypertension, HbA1c, and lipid levels. However, more patients in the dapagliflozin group had diabetes (68.6% vs. 31.4%, p = 0.007). Both drugs significantly lowered systolic blood pressure and improved ejection fraction. Dapagliflozin caused a larger drop in sodium levels (2.51 vs 0.83 mEq/L, p = 0.007). Among diabetic patients, empagliflozin reduced blood glucose by a greater amount (-75.00 vs -42.33…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.